ANAVEX3-71 oral capsules + Placebo oral capsules
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Mar 15, 2024 → Jun 30, 2025
NCT ID
NCT06245213About ANAVEX3-71 oral capsules + Placebo oral capsules
ANAVEX3-71 oral capsules + Placebo oral capsules is a phase 2 stage product being developed by Anavex Life Sciences for Schizophrenia. The current trial status is active. This product is registered under clinical trial identifier NCT06245213. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06245213 | Phase 2 | Active |
Competing Products
20 competing products in Schizophrenia